American Cancer Society
Overview
Nationwide health organization dedicated to eliminating cancer.
Founded
1913
Deals ยท 12mo
4
Stage focus
Geographic focus
Sector focus
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
Cloverleaf Bio | Sep 2026Participated | $33 MSeed | |
TippingPoint Biosciences | Mar 2026Participated | $5 MSeed | |
Cellens | Dec 2025Participated | $7 MSeed | |
Paradigm | Dec 2025Participated | $78 MSeries B | |
Signify Bio | Jun 2025Participated | $15 MOther Equity | |
CellCentric | May 2025Participated | $120 MSeries C | |
Predicta Biosciences | Jul 2024Participated | $5 MSeed | |
Freenome | Feb 2024Participated | $254 MOther Equity | |
Paradigm | Jan 2023Participated | $203 MSeries A | |
Persephone Biosciences | Jul 2022Participated | $15 MSeed | |
TailorMed | Sep 2021Participated | $25 MOther Equity | |
TailorMed | Sep 2021Participated | $25 MOther Equity | |
Cloverleaf Bio | Sep 2026Participated | $33 MSeed | |
TippingPoint Biosciences | Mar 2026Participated | $5 MSeed | |
Cellens | Dec 2025Participated | $7 MSeed | |
Paradigm | Dec 2025Participated | $78 MSeries B | |
Signify Bio | Jun 2025Participated | $15 MOther Equity | |
CellCentric | May 2025Participated | $120 MSeries C | |
Predicta Biosciences | Jul 2024Participated | $5 MSeed | |
Freenome | Feb 2024Participated | $254 MOther Equity | |
Paradigm | Jan 2023Participated | $203 MSeries A | |
Persephone Biosciences | Jul 2022Participated | $15 MSeed | |
TailorMed | Sep 2021Participated | $25 MOther Equity | |
TailorMed | Sep 2021Participated | $25 MOther Equity |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 0 | 5 |
| Series A | 0 | 2 |
| Series B | 0 | 2 |
| Series C+ | 0 | 2 |
| Other Equity | 0 | 4 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Jul '19 | 1 |
| Aug '19 | 0 |
| Sep '19 | 0 |
| Oct '19 | 0 |
| Nov '19 | 0 |
| Dec '19 | 0 |
| Jan '20 | 0 |
| Feb '20 | 0 |
| Mar '20 | 0 |
| Apr '20 | 0 |
| May '20 | 0 |
| Jun '20 | 0 |
| Jul '20 | 0 |
| Aug '20 | 1 |
| Sep '20 | 0 |
| Oct '20 | 0 |
| Nov '20 | 0 |
| Dec '20 | 0 |
| Jan '21 | 0 |
| Feb '21 | 0 |
| Mar '21 | 0 |
| Apr '21 | 0 |
| May '21 | 1 |
| Jun '21 | 0 |
| Jul '21 | 0 |
| Aug '21 | 0 |
| Sep '21 | 2 |
| Oct '21 | 0 |
| Nov '21 | 0 |
| Dec '21 | 0 |
| Jan '22 | 0 |
| Feb '22 | 0 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 0 |
| Jun '22 | 0 |
| Jul '22 | 1 |
| Aug '22 | 0 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 0 |
| Jan '23 | 1 |
| Feb '23 | 0 |
| Mar '23 | 0 |
| Apr '23 | 0 |
| May '23 | 0 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 1 |
| Mar '24 | 0 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 1 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 1 |
| Jun '25 | 1 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 0 |
| Dec '25 | 2 |
| Jan '26 | 0 |
| Feb '26 | 0 |
| Mar '26 | 1 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 1 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 15 |
| AI & Machine Learning | 2 |
| Fintech | 1 |
| Manufacturing | 1 |
| Consumer & Lifestyle | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 1 |
| $5M-$10M | 2 |
| $10M-$25M | 2 |
| $25M-$50M | 3 |
| $50M-$100M | 2 |
| $100M-$250M | 3 |
| $250M-$500M | 2 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 3 of 3 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 12 |
| Israel | 2 |
| Europe | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| BrightEdge | 5 |
| RA Capital Management | 5 |
| Google Ventures | 4 |
| Andreessen Horowitz | 3 |
| Bain Capital Life Sciences | 3 |
| Data Collective | 3 |
| Perceptive Advisors | 3 |
| Polaris Partners | 3 |
| Roche Venture | 3 |
| T. Rowe Price Associates | 3 |
| ARCH Venture Partners | 2 |
| Citi | 2 |
| Cormorant Asset Management | 2 |
| Eli Lilly and Company | 2 |
| F-Prime Capital | 2 |
| General Catalyst | 2 |
| Kaiser Permanente Ventures | 2 |
| Lux Capital | 2 |
| Mubadala Capital | 2 |
| OSF Ventures | 2 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 0 | 0% |
| Participating | 15 | 100% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 0 | 0% |
| Co-led | 0 | 0% |
Lead dynamics requires at least one led deal in this range
Team
Research Scholar
Cancer Support Strategic Partnerships Manager
Diversity Advisory Committee Member
Member of the American Cancer Society's DetermiNation Endurance Team and Volunteer Committee
Chief Financial Officer
Volunteer
Club Member
President